Acurx Pharmaceuticals, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 1.04 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 5.48M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus (MRSA), vancomycin resistant enterococcus (VRE), and drug-resistant streptococcus pneumoniae (DRSP), as well as B. anthracis. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Details
| Name | Acurx Pharmaceuticals, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 4 |
| Founded | 2017 |
| Ipo Date | 2021-06-25 |
| Ceo | David Luci |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 6.00 |
| Isin | US00510M2035 |
| Cusip | 00510M203 |
| Cik | 1736243 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Robert J. DeLuccia | Co-Founder and Executive Chairman |
| Robert G. Shawah CPA | Co-Founder and Chief Financial Officer |
| Dr. Michael H. Silverman B.Sc., F.A.C.P., FACR, M.B.A., M.D. | Medical Director |
Contact
| Address | 259 Liberty Avenue, Staten Island, New York 10305, United States |
| Phone | 917 533 1469 |
| Website | https://www.acurxpharma.com |